Shattuck Labs (NASDAQ: STTK) is a biotechnology company that develops treatments for inflammatory and immune-related diseases. Its main focus is on its lead drug candidate, SL-325. This drug is a potential first-in-class antibody designed to target the DR3 receptor, which may help patients with conditions like inflammatory bowel disease.
On June 9, 2026, Citigroup showed strong confidence in the company's direction. The firm kept its "Buy" rating for Shattuck Labs and more than doubled its price target, raising it to $18.00 from the previous $7.00. At the time, the stock was trading at a price of $3.90 per share.
This optimism follows Shattuck's announcement of positive results from its Phase 1 clinical trial for SL-325. As highlighted by GlobeNewswire, the trial showed a favorable safety profile. The drug was well-tolerated and had a low immunogenicity profile, with only 3.7% of participants developing antidrug antibodies, which can sometimes reduce a drug's effectiveness.
Despite the positive trial data and analyst upgrade, Shattuck Labs' stock traded lower, dropping 14.85% to $3.90, as noted by Benzinga. The stock's daily price moved between a low of $3.33 and a high of $5.03. This type of price drop can sometimes occur after good news if investor expectations were already high.
Following the successful Phase 1 results, Shattuck plans to begin a Phase 2b clinical trial in the third quarter of 2026. A Phase 2 trial is a critical step that tests a drug's effectiveness on a larger group of patients, moving it closer to potential market approval.
